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Background: Cryptococcal meningitis (CM) accounts for 10–20% of
HIV-related deaths and >100,000 deaths/year. Amphotericin (AmB)
plus flucytosine for 2 weeks is considered the gold standard but is
unavailable in resource-limited settings where fluconazole treat-
ment predominates.
Methods: Based on Phase II studies, we tested, against 2 weeks
AmB-based treatment, 2 new strategies, which could be sustain-
able in Africa, and more effective than fluconazole: optimized oral
therapy of high dose fluconazole plus flucytosine, and short
(1 week) induction with AmB-based treatment. In the AmB arms,
we compared fluconazole and flucytosine as adjunctive treatments.
Between 2013 and 2016, 721 participants from 9 centres in
Malawi, Zambia, Cameroon and Tanzania with first-episode CM
were randomized to:
Oral (238): fluconazole (1200mg/day) plus flucytosine (100mg/kg/
day) for 2 weeks.
1-week (240): AmB (1mg/kg/d), plus fluconazole (1200mg/day), or
flucytosine (100mg/kg/day) (ratio 1:1), for 7 days. Days 8–14,
fluconazole 1200mg/day.
2-weeks (243): AmB (1mg/kg/d) plus fluconazole (1200mg/day), or
flucytosine (100mg/kg/day) (ratio 1:1), for 14 days.
After 2 weeks, all received standard fluconazole consolidation. ART
was started, or restarted, at 4 weeks, and patients followed-up to
10 weeks.
Results: Only 4 participants were lost-to-follow-up. Mortality at 2
and 10 weeks for oral, 1-week and 2-weeks was 18%, 22%, 21%,
and 35%, 36%, 40%, respectively. The upper 1-sided 95% CI limits
for the difference in mortality comparing oral and 1-week against
2 weeks AmB-based treatment (primary endpoint) were 3.0% and
6.8%, below the pre-specified 10% non-inferiority margin. Hazard
ratios (95% CI) were 0.82 (0.54–1.25) and 1.01 (0.68–1.51) at 2,
and 0.83 (0.61–1.13) and 0.89 (0.66–1.21) at 10 weeks, for oral and
1-week versus 2-weeks, respectively. As adjunctive treatment with
AmB, flucytosine was superior to fluconazole (HR(95% CI): 1.62
(1.19–2.20) p = 0.002). One week AmB plus flucytosine had the
lowest 10-week mortality (24%), significantly lower than all other
AmB arms (HR(95%CI): 0.56(0.35–0.91) comparing 1-week with 2-
weeks AmB plus flucytosine). Side effects were more frequent with
2 weeks AmB than with 1 week AmB, or oral therapy.
Conclusions: One week AmB plus flucytosine and the oral combi-
nation provide safe, effective and sustainable induction therapy in
resource-limited settings. Flucytosine should be made widely avail-
able for treatment of cryptococcosis.
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